Landry Robert E sold $72K of CYTK
Landry Robert E sold 1,000 shares of CYTOKINETICS INC (CYTK) at $72.13 on 2026-09-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and pre‑arranged, suggesting minimal immediate market reaction.
Market read
Small insider sale with limited trading relevance; unlikely to move the stock.
What to watch
The 10b5‑1 plan may have been set months ago; the timing does not reflect current company fundamentals.
Background
Form 4 filings disclose insider transactions; they are primary sources for regulatory reporting.
Ticker impact
Director Robert E. Landry sold 1,000 shares for $72,130 via a 10b5‑1 plan on Sep 15, 2026.
No material move expected; possible slight downward bias.
The sale represents less than 0.2% of total shares held and follows a pre‑arranged plan, indicating no new negative information about the company.
Market effects
None; Cytokinetics operates in biotech, but the insider sale is too small to affect sector sentiment.
None; limited to the individual stock.
None
Counterpoint
If the director anticipates near‑term weakness, the sale could hint at upcoming downside.
Key entities
- CompanyCytokinetics Inc.
Biopharmaceutical company developing cardiac and skeletal muscle therapeutics.
- InsiderRobert E. Landry
Director of Cytokinetics who sold shares.
